Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Duality BiotherapeuticsFRA:4ZB -1.02%19 3-Year Share Buyback Ratio is -2.40 as of Jun. 2026. GuruFocus rates FRA:4ZB with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 1,186 Biotechnology companies, Duality Biotherapeutics ranks better than 75.72% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Duality Biotherapeutics's current 3-Year Share Buyback Ratio was -2.40%.
The historical rank and industry rank for Duality Biotherapeutics's 3-Year Share Buyback Ratio or its related term are showing as below:
FRA:4ZB'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -2.4 Med: -2.4 Max: -2.4
Current: -2.4
During the past 4 years, Duality Biotherapeutics's highest 3-Year Share Buyback Ratio was -2.40%. The lowest was -2.40%. And the median was -2.40%.
FRA:4ZB's 3-Year Share Buyback Ratio is ranked better than 75.72% of 1186
companies
in the Biotechnology industry
Industry Median: -11.6
vs FRA:4ZB: -2.40
Duality Biotherapeutics (FRA:4ZB) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Duality Biotherapeutics 3-Year Share Buyback Ratio Related Terms
FRA:4ZB vs VRTX, REGN, MRNA: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Duality Biotherapeutics's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Duality Biotherapeutics 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Duality Biotherapeutics's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Duality Biotherapeutics's 3-Year Share Buyback Ratio falls into.
Duality Biotherapeutics 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -2.40 mean?
Duality Biotherapeutics (FRA:4ZB) has a 3-Year Share Buyback Ratio of -2.40 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Duality Biotherapeutics and its competitors. According to the industry distribution chart, Duality Biotherapeutics ranks #288 out of 1186 companies in the Biotechnology industry, placing it in the top 24.3%.
Is Duality Biotherapeutics' 3-Year Share Buyback Ratio too high?
Duality Biotherapeutics' current 3-Year Share Buyback Ratio is -2.40. Based on the distribution chart, Duality Biotherapeutics ranks #288 out of 1186 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Duality Biotherapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Duality Biotherapeutics' 3-Year Share Buyback Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Duality Biotherapeutics ranks #288 out of 1186 companies for 3-Year Share Buyback Ratio. This places Duality Biotherapeutics in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Duality Biotherapeutics and its competitors. Duality Biotherapeutics's current 3-Year Share Buyback Ratio is -2.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duality Biotherapeutics stock overvalued right now?
Duality Biotherapeutics (FRA:4ZB) has a current 3-Year Share Buyback Ratio of -2.40. The current 3-Year Share Buyback Ratio is -2.40. Duality Biotherapeutics' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Duality Biotherapeutics (FRA:4ZB), the current 3-Year Share Buyback Ratio is -2.40 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Duality Biotherapeutics Inc is engaged in the discovery and development of antibody-drug conjugate (ADC) therapeutics, focusing on treatments for cancer and other diseases. The company has a diversified pipeline of ADC candidates, including two core products: DB-1303/BNT323, a HER2-targeting ADC for cancers such as breast and endometrial cancer, and DB-1311/BNT324, a B7-H3-targeting ADC for multiple solid tumors. In addition, it has several other clinical-stage ADC candidates with therapeutic potential, as well as multiple preclinical ADCs, including candidates expected to enter clinical trials. Its key products, including DB-1303/BNT323, DB-1311/BNT324, and DB-1305/BNT325, have received Fast Track Designation, with DB-1303 being a late-stage candidate undergoing registrational studies.
19GF Score
Get the complete analysis for FRA:4ZB
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4ZB has been successfully added to your 
